Hyaluronic acid fuels pancreatic cancer cell growth
Abstract
Rewired metabolism is a hallmark of pancreatic ductal adenocarcinomas (PDA). Previously, we demonstrated that PDA cells enhance glycosylation precursor biogenesis through the hexosamine biosynthetic pathway (HBP) via activation of the rate limiting enzyme, glutamine-fructose 6-phosphate amidotransferase 1 (GFAT1). Here, we genetically ablated GFAT1 in human PDA cell lines, which completely blocked proliferation in vitro and led to cell death. In contrast, GFAT1 knockout did not preclude the growth of human tumor xenografts in mice, suggesting that cancer cells can maintain fidelity of glycosylation precursor pools by scavenging nutrients from the tumor microenvironment. We found that hyaluronic acid (HA), an abundant carbohydrate polymer in pancreatic tumors composed of repeating N-acetyl-glucosamine (GlcNAc) and glucuronic acid sugars, can bypass GFAT1 to refuel the HBP via the GlcNAc salvage pathway. Together, these data show HA can serve as a nutrient fueling PDA metabolism beyond its previously appreciated structural and signaling roles.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting file; raw images have been provided for all western blots in the Source Data file.
Article and author information
Author details
Funding
National Cancer Institute (Cancer Biology Training Grant,T32AI007413)
- Peter K Kim
- Samuel A Kerk
Thompson Family Foundation (Research Grant)
- Kayvan R Keshari
STARR Cancer Consortium (Research Grant)
- Kayvan R Keshari
National Cancer Institute (Cancer Center Support Grant,P30CA008748)
- Kayvan R Keshari
American Association for Cancer Research (Pathway to Leadership award,13-70-25-LYSS)
- Costas A Lyssiotis
V Foundation for Cancer Research (Junior Scholar Award,V2016-009)
- Costas A Lyssiotis
Sidney Kimmel Foundation (Kimmel Scholar Award,SKF-16-005)
- Costas A Lyssiotis
American Association for Cancer Research (NextGen Grant for Transformative Cancer Research,17-20-01-LYSS)
- Costas A Lyssiotis
National Cancer Institute (Cancer Center Support Grant,P30 CA046592)
- Costas A Lyssiotis
National Cancer Institute (R37CA237421)
- Costas A Lyssiotis
National Cancer Institute (R01CA248160)
- Costas A Lyssiotis
National Cancer Institute (Predoctoral Fellowship,F31CA243344)
- Peter K Kim
National Cancer Institute (R01CA244931)
- Costas A Lyssiotis
National Institutes of Health (U24DK097153)
- Costas A Lyssiotis
Charles Woodson Research Fund (Research Support)
- Costas A Lyssiotis
UM Pediatric Brain Tumor Initiative (Research Support)
- Costas A Lyssiotis
National Cancer Institute (F99/K00CA264414)
- Samuel A Kerk
National Institute of Child Health and Human Development (T32HD007505)
- Megan Radyk
National Cancer Institute (Pathway to Independence Award,K99CA241357)
- Christopher J Halbrook
National Institute of Diabetes and Digestive and Kidney Diseases (Postdoctoral Support,P30DK034933)
- Christopher J Halbrook
National Cancer Institute (F31CA24745701)
- Samuel A Kerk
National Cancer Institute (R01CA237466)
- Kayvan R Keshari
National Cancer Institute (R01CA252037)
- Kayvan R Keshari
National Cancer Institute (R21CA212958)
- Kayvan R Keshari
Stand Up To Cancer (Research Grant)
- Kayvan R Keshari
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Lydia W S Finley, Memorial Sloan Kettering Cancer Center, United States
Ethics
Animal experimentation: Animal experiments were conducted in accordance with the Office of Laboratory Animal Welfare and approved by the Institutional Animal Care and Use Committees of the University of Michigan. Protocol#: PRO00008877
Version history
- Received: September 1, 2020
- Accepted: December 21, 2021
- Accepted Manuscript published: December 24, 2021 (version 1)
- Accepted Manuscript updated: December 29, 2021 (version 2)
- Version of Record published: January 5, 2022 (version 3)
Copyright
© 2021, Kim et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 8,933
- views
-
- 901
- downloads
-
- 50
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
BRAFV600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAFV600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a ‘just-right’ level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAFV600E-mutant adenomas/polyps in mice and patients. In Vil1-Cre;BRAFLSL-V600E/+;Ptk2fl/fl mice, Fak deletion maximized BRAFV600E’s oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAFV600E-induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a ‘just-right’ ERK signaling optimal for BRAFV600E-induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.
-
- Cancer Biology
- Computational and Systems Biology
Untargeted metabolomic profiling through liquid chromatography-mass spectrometry (LC-MS) measures a vast array of metabolites within biospecimens, advancing drug development, disease diagnosis, and risk prediction. However, the low throughput of LC-MS poses a major challenge for biomarker discovery, annotation, and experimental comparison, necessitating the merging of multiple datasets. Current data pooling methods encounter practical limitations due to their vulnerability to data variations and hyperparameter dependence. Here, we introduce GromovMatcher, a flexible and user-friendly algorithm that automatically combines LC-MS datasets using optimal transport. By capitalizing on feature intensity correlation structures, GromovMatcher delivers superior alignment accuracy and robustness compared to existing approaches. This algorithm scales to thousands of features requiring minimal hyperparameter tuning. Manually curated datasets for validating alignment algorithms are limited in the field of untargeted metabolomics, and hence we develop a dataset split procedure to generate pairs of validation datasets to test the alignments produced by GromovMatcher and other methods. Applying our method to experimental patient studies of liver and pancreatic cancer, we discover shared metabolic features related to patient alcohol intake, demonstrating how GromovMatcher facilitates the search for biomarkers associated with lifestyle risk factors linked to several cancer types.